Background: Expert guidelines recommend reducing or discontinuing long-term opioid therapy (LTOT) when risks outweigh benefits, but evidence on the effect of dose reduction on patient outcomes has not been systematically reviewed.
A pproximately 10 million U.S. adults are prescribed long-term opioid therapy (LTOT) for chronic pain despite inadequate evidence of long-term benefit and growing evidence of harms (1, 2) . No published studies have compared LTOT (>1 year) versus placebo, no opioid, or nonopioid therapies (2) . In recent decades, a dramatic increase in the prescription of opioid medications has been accompanied by increases in opioid overdose (3); more than 33 000 opioid overdose deaths occurred in 2015 (4). Higher prescribed opioid dose is associated with overdose risk (5-7) as well as incidence of opioid use disorder, depression, fracture, motor vehicle accident, and suicide (8 -12) . Dose reduction or discontinuation, or opioid tapering, may decrease these risks, and expert guidelines recommend tapering when risks outweigh benefits (13, 14) .
Opioid tapering can be challenging for both patients and clinicians. In routine practice, discontinuation of LTOT is uncommon, ranging from 8% to 35% in prior cohort studies (15, 16) . In a survey of patients receiving high-dose opioid medications for chronic pain, nearly half reported wanting to cut down or stop, yet 80% were receiving high-dose opioids 1 year later (17) . Among patients who had a nonfatal overdose while being prescribed LTOT, 91% continued use of opioid medications after the overdose (18). There is little evidence to guide clinicians in the process of opioid tapering, especially in primary care settings, where most opioid therapy is prescribed (19, 20) . In addition, little is known about the risks and benefits of opioid tapering. Potential risks include withdrawal symptoms, increased pain, and loss to follow-up (20). However, some patients report improvements in function and quality of life after tapering (21). The effects of opioid tapering on patient outcomes have not been systematically reviewed.
To address these gaps, we systematically reviewed the evidence on the effectiveness of strategies to reduce or discontinue LTOT prescribed for chronic pain (25-92) (Appendix Figure, available at Annals.org). These studies included 11 randomized controlled trials, 8 controlled observational studies, and 48 uncontrolled observational studies. Studies presented data on 12 546 patients (range, 5 to 1457 patients); 10 studies conducted at a single center (32, 33, 36, 44 -48, 70, 80) and 2 studies each at 3 centers (37, 49, 50, 52, 63, 64) may have included data on individual participants in more than 1 study. We categorized studies into 8 mutually exclusive intervention types: interdisciplinary pain programs, buprenorphine-assisted dose reduction, behavioral interventions, detoxification, ketamine-assisted dose reduction, acupuncture, other outpatient programs, and other interventional programs ( Table 1) . Interventions occurred in outpatient settings, inpatient settings, or both in 42, 15 , and 10 studies, respectively; 5 studies were conducted in primary care settings. Among 48 studies reporting baseline opioid dose for Interventions supported opioid dose reduction with symptomatic medications (e.g., clonidine and benzodiazepines) 2 outpatient studies, 1 inpatient study, and 1 study in both settings Mean opioid discontinuation rate, 91% (range, 91%-100%); 3 studies participants receiving LTOT, the mean daily dose ranged from 29 to 556 mg MED. Study interventions had an objective of opioid discontinuation or dose reduction in 43 and 12 studies, respectively; 12 studies reported on this outcome in secondary or exploratory analyses. All included studies assessed the effectiveness of strategies to reduce or discontinue LTOT (key question 1). Study quality as assessed by the USPSTF criteria was good for 3 studies, fair for 13 studies, and poor for 51 studies. The GRADE quality of evidence to address the effectiveness of strategies to reduce or discontinue LTOT was very low ( Table 2 ; Appendix Table 4 , available at Annals.org). In the remainder of this section, we highlight results from good-and fair-quality studies. Descriptions of all included studies are available in Appendix Table 5 (available at Annals.org).
Thirty-one studies (11 fair-quality and 20 poorquality) presented data from 19 distinct interdisciplinary pain programs. These programs were described as intensive multimodal treatment with an interdisciplinary team, typically organized around a biopsychosocial model of chronic pain. The 11 fair-quality studies included 2 controlled and 9 uncontrolled observational studies. Ten fair-quality studies described programs that mandated discontinuation as a condition of enrollment; in these programs, 87% of participants discontinued opioid use at program completion (range, 74% to 100%).
Six studies (3 good-quality and 3 poor-quality) with 238 total participants assessed the effectiveness of behavioral interventions. The 3 good-quality studies were small randomized controlled trials; 2 were described as pilot trials, and none were powered to detect clinically meaningful differences in opioid dose reduction. The first good-quality trial compared a 4-month interactive voice response intervention versus usual care among patients with chronic pain (n = 51); a goal of opioid dose reduction was optional. The intervention reduced the mean opioid dose significantly at 4-month (P = 0.04) and 8-month (P = 0.004) follow-up compared with usual care (mean dose change was not reported) (65). The second good-quality trial compared an 8-week group intervention based on mindfulness meditation and cognitive behavioral therapy with usual care among patients receiving LTOT (n = 35); the intervention did not explicitly encourage dose reduction. The mean change in the daily opioid dose from baseline to 26 weeks was Ϫ10.1 mg MED in the intervention group compared with Ϫ0.2 mg MED in the control group (P = 0.8) (90). The third good-quality trial compared a 22-week opioid taper support intervention (motivational interviewing and pain self-management education delivered by a physician assistant) with usual care (n = 35); opioid dose reduction was the primary outcome. The intervention reduced the mean opioid dose by 43% compared with 19% in the usual care group at 22 weeks (P = 0.07) (76). The remaining 6 intervention types were described in 30 studies (2 fair-quality and 28 poor-quality).
We identified 40 studies that examined the effect of dose reduction or discontinuation of LTOT on patient outcomes (key question 2) ( Table 3) . These studies included 5 randomized controlled trials, 6 controlled observational studies, and 29 uncontrolled observational studies. None of the 40 studies were rated as good-quality. For each of the 6 prespecified patient outcomes, the GRADE quality of evidence was very low ( Table 2 and Appendix Table 4) .
Thirty-six studies (8 fair-quality and 28 poor-quality) examined the effect of opioid dose reduction on pain severity. The 8 fair-quality studies included 1 controlled and 6 uncontrolled observational studies of interdisciplinary pain programs and 1 uncontrolled observational study of acupuncture; all 8 studies reported improved pain after opioid dose reduction. The effect of dose reduction on pain-related function was assessed in 17 studies (5 fair-quality and 12 poor-quality). The 5 fair-quality studies were observational studies of interdisciplinary pain programs (1 controlled and 4 uncontrolled); all 5 studies reported improved function after opioid dose reduction. The effect of dose reduction on quality of life was assessed in 12 studies (3 fair-quality and 9 poor-quality). The 3 fair-quality studies were uncontrolled observational studies of interdisciplinary pain programs; all reported improved quality of life after opioid dose reduction. Opioid withdrawal symptoms were examined in 18 studies (3 fair-quality and 15 poor-quality); the reported incidence during opioid dose reduction ranged widely. Four poor-quality studies examined new-onset substance use. Eleven poorquality studies assessed adverse events; 5 assessed mortality outcomes, and 1 reported a single opioidrelated overdose death.
DISCUSSION
This systematic review identified 67 studies that examined the effectiveness of strategies to reduce or discontinue LTOT among adults with chronic pain, including 3 small good-quality randomized trials, 1 fairquality randomized trial, and 12 fair-quality observational studies. Though many studies reported positive dose reduction outcomes, the overall quality of the evidence for effectiveness of all strategies to reduce or discontinue LTOT was very low due to methodological limitations across studies and an absence of adequately powered randomized trials. We identified 40 studies that assessed the effect of dose reduction or discontinuation of LTOT on important patient outcomes, 8 of which were fair-quality observational studies. The fairquality studies reported improvement in pain severity (8 of 8 studies), function (5 of 5 studies), and quality of life (3 of 3 studies) after opioid dose reduction. However, the overall quality of the evidence was very low for all 6 prespecified patient outcomes.
Common themes across intervention types can provide insight into the program components that may provide effective support for opioid tapering. In the 3 good-quality trials of behavioral interventions and the 11 fair-quality studies of interdisciplinary pain programs, patients received multimodal care that emphasized nonpharmacologic and self-management strategies. Such care is consistent with expert guidelines for management of LTOT and chronic pain (13, 14, 93) . In addition to the content of these interventions, the quantity of care provided is likely an important factor. Multidisciplinary care and close follow-up (at least weekly) were common attributes of evaluated programs in good-and fair-quality studies. Such team- based, intensive support would require additional resources to implement in primary care settings, where most opioid medications are prescribed (19) . Given the heterogeneity across interventions and the overall poor quality of studies, data do not currently support assessment of comparative effectiveness of the different models of care or opioid tapering protocols used in included studies. Although confidence is limited by the very low quality of evidence overall, findings from this systematic review suggest that pain, function, and quality of life may improve during and after opioid dose reduction. Several potential mechanisms may underlie this finding. First, in addition to tapering opioids, most interventions delivered concurrent nonopioid pain management approaches that may have provided more benefit than LTOT. Second, opioid dose reduction may alleviate adverse effects of LTOT that can negatively affect function and quality of life, such as constipation, fatigue, poor sleep, and depressed mood. Third, improvement after opioid dose reduction may result from resolution of opioid-induced hyperalgesia, a paradoxical response in which patients receiving opioids become more sensitive to painful stimuli (94). Finally, given the observational nature of most studies, we cannot exclude reverse causation (that is, patients successfully tapered opioids because pain severity decreased). In the realm of opioid therapy, patient safety and pain relief have often been framed as conflicting and mutually exclusive goals. Evidence about benefits of opioid tapering for pain, function, and quality of life, if confirmed by future high-quality studies, holds the poten- Three prior systematic reviews identified 11 randomized or controlled studies of interventions for dose reduction among patients prescribed opioid medications for chronic pain (2, 95, 96) . All 3 reviews determined that the strength of evidence was insufficient to draw conclusions. Our review extends these prior reviews by providing an updated and comprehensive assessment of the literature, adding 2 recent goodquality randomized controlled trials and 11 fair-quality observational studies. Whereas prior reviews assessed outcomes of opioid dose reduction, this is, to our knowledge, the first study to systematically review patient outcomes after dose reduction or discontinuation of LTOT for chronic pain.
The findings of this systematic review should be interpreted in the context of its limitations. First, there was substantial heterogeneity of measures of opioid dose reduction and patient outcomes. Second, we categorized interventions into clinically relevant domains according to the authors' descriptions of key components. There was substantial heterogeneity within domains and overlap across some. Third, most of the included studies examined voluntary participation in a clinical program or research intervention. The findings may therefore not be generalizable to patients for whom LTOT is reduced or discontinued involuntarily. Fourth, publication bias may have limited the evidence that was available for this review. Finally, new data may have emerged since April 2017 in this rapidly evolving area; 39 of the 67 studies included in this review were published since 2010, and 18 were published since 2015.
This systematic review highlights challenges and opportunities for future research (Table 4) . First, measurement and reporting of opioid dose reduction were heterogeneous across studies, and consensus on what constitutes meaningful dose reduction is needed, including patients transitioning to buprenorphine. Second, innovative strategies for recruitment and retention will be required for future patient-level randomized trials of opioid tapering because patients' apprehension with regard to tapering may serve as a barrier to participation (21). Such strategies might include randomization of patients to active pain management interventions with optional opioid dose reduction, randomization to different protocols or tapering rates among motivated patients, or randomization at the level of the prescriber or facility. Given that loss to follow-up was common in poor-quality studies in this review, evidence on effective strategies to enhance patient engagement is also needed. Third, future research should examine strategies that are likely to be feasible in busy primary care settings and scalable across health systems. Although 31 studies in this review examined interdisciplinary pain programs, only 5 involved primary care settings. The effectiveness of less resourceintensive team-based models (97, 98) or technologyassisted approaches (99) for supporting opioid tapering warrants further study. Fourth, in the context of ongoing health system and population-level efforts to reduce opioid use and prevent opioid-related harms (100 -102), we identified no prospective studies of mandatory, involuntary opioid dose reduction among otherwise stable patients. Finally, this review found insufficient evidence on adverse events related to opioid tapering, such as accidental overdose if patients resume use of high-dose opioids or switch to illicit opioid sources or onset of suicidality or other mental health symptoms. Public health surveillance and large-scale observational studies are needed to assess outcomes of efforts to reduce opioid prescribing at the health system and population levels, especially rare but important adverse events, such as overdose and suicide.
In conclusion, this systematic review identified multiple strategies to reduce or discontinue LTOT for chronic pain and found very-low-quality evidence that opioid dose reduction may improve pain, function, and quality of life. In addition to discussing the goals and risks of opioid therapy, clinicians should consider discussing the potential benefits of opioid tapering with patients receiving LTOT. Informed by the multidisciplinary care models among good-and fair-quality studies, clinicians should consider referring patients to multidisciplinary pain programs, when available, or developing team-based approaches to support opioid tapering in outpatient practice. Finally, given inadequate evidence on the risks of opioid tapering, caution and close monitoring are warranted during and after tapering; consideration of overdose prevention strategies, such as naloxone, may be prudent (103). Together, these strategies are well-aligned with the broader goal of patient-centered, evidence-based, effective chronic pain care (104). 
Appendix Table 2. USPSTF Quality Rating Criteria for RCTs and Cohort Studies
Criteria Initial assembly of comparable groups: RCTs-adequate randomization, including concealment and whether potential confounders were distributed equally among groups Cohort studies-consideration of potential confounders with either restriction or measurement for adjustment in the analysis; consideration of inception cohorts Maintenance of comparable groups (includes attrition, crossovers, adherence, contamination) Important differential loss to follow-up or overall high loss to follow-up Measurements: equal, reliable, and valid (includes masking of outcome assessment) Clear definition of interventions Important outcomes considered Analysis: adjustment for potential confounders for cohort studies, or intention-to-treat analysis for RCTs (i.e., analysis in which all participants in a trial are analyzed according to the intervention to which they were allocated, regardless of whether or not they completed the intervention)
Definition of ratings based on above criteria
Good Meets all criteria: Comparable groups are assembled initially and maintained throughout the study (follow-up at least 80%); reliable and valid measurement instruments are used and applied equally to the groups; interventions are spelled out clearly; important outcomes are considered; and appropriate attention to confounders in analysis. Fair Studies will be graded "fair" if any or all of the following problems occur, without the important limitations noted in the "poor" category below: Generally comparable groups are assembled initially but some question remains whether some (although not major) differences occurred in follow-up; measurement instruments are acceptable (although not the best) and generally applied equally; some but not all important outcomes are considered; and some but not all potential confounders are accounted for. Poor Studies will be graded "poor" if any of the following major limitations exists: Groups assembled initially are not close to being comparable or maintained throughout the study; unreliable or invalid measurement instruments are used or not applied at all equally among groups (including not masking outcome assessment); and key confounders are given little or no attention. RCT = randomized controlled trial; USPSTF = U.S. Preventive Services Task Force. 
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